GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BICO Group AB (OTCPK:CLLKF) » Definitions » Sloan Ratio %

CLLKF (BICO Group AB) Sloan Ratio % : -35.80% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BICO Group AB Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

BICO Group AB's Sloan Ratio for the quarter that ended in Sep. 2024 was -35.80%.

Warning Sign:

When sloan ratio (-25.73)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Sep. 2024, BICO Group AB has a Sloan Ratio of -35.80%, indicating earnings are more likely to be made up of accruals.


BICO Group AB Sloan Ratio % Historical Data

The historical data trend for BICO Group AB's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BICO Group AB Sloan Ratio % Chart

BICO Group AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial 20.99 12.78 47.52 -7.61 -25.73

BICO Group AB Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.24 -25.57 -32.90 -30.05 -35.80

Competitive Comparison of BICO Group AB's Sloan Ratio %

For the Medical Devices subindustry, BICO Group AB's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BICO Group AB's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BICO Group AB's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where BICO Group AB's Sloan Ratio % falls into.



BICO Group AB Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

BICO Group AB's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-193.33-17.392
--12.644)/769.946
=-25.73%

BICO Group AB's Sloan Ratio for the quarter that ended in Sep. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2024 )
=(-167.951-13.676
-9.872)/534.871
=-35.80%

BICO Group AB's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -133.745 (Dec. 2023 ) + -2.709 (Mar. 2024 ) + -7.428 (Jun. 2024 ) + -24.069 (Sep. 2024 ) = $-168.0 Mil.
BICO Group AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was 15.793 (Dec. 2023 ) + -1.662 (Mar. 2024 ) + -4.854 (Jun. 2024 ) + 4.399 (Sep. 2024 ) = $13.7 Mil.
BICO Group AB's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was 18.874 (Dec. 2023 ) + -4.178 (Mar. 2024 ) + -2.155 (Jun. 2024 ) + -2.669 (Sep. 2024 ) = $9.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BICO Group AB  (OTCPK:CLLKF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2024, BICO Group AB has a Sloan Ratio of -35.80%, indicating earnings are more likely to be made up of accruals.


BICO Group AB Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of BICO Group AB's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


BICO Group AB Business Description

Traded in Other Exchanges
Address
Langfilsgatan 9, Gothenburg, SWE, 41277
BICO Group AB is a bio-convergence company. It is divided into three business areas: Bioprinting (CELLINK, MatTek, Visikol, and Nanoscribe), Biosciences (CYTENA, CYTENA Bioprocess Solutions, Dispendix, and Discover Echo), and Bioautomation (SCIENION, CELLENION, and Ginolis).